Amgen

Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China

Amgen Inc. (NASDAQ: AMGN) announced that China’s National Medical Products Administration (NMPA) has granted marketing...

Company

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Fineline Cube May 6, 2026

Amgen (NASDAQ: AMGN) announced on May 4, 2026, an additional $300 million investment in its...

Company Drug

Mabwell Bioscience Secures Second NMPA Approval for Denosu, China’s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma

Fineline Cube Apr 16, 2026

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China’s...

Company Drug

BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer

Fineline Cube Apr 10, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China’s National...

Company Drug

Amgen’s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response

Fineline Cube Apr 7, 2026

Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating...

Company Deals Drug

Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Apr 2, 2026

Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Amgen Inc. (NASDAQ: AMGN) announced a strategic collaboration...

Company Drug

Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels

Fineline Cube Mar 31, 2026

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced FDA marketing approval for Ponlimsi, its biosimilar...

Company Drug

AstraZeneca’s Tezspire Gains Dual NMPA Approvals in China for Severe Asthma and Nasal Polyps Based on Pivotal Phase III Data

Fineline Cube Mar 30, 2026

AstraZeneca plc (NYSE: AZN) announced that China’s National Medical Products Administration (NMPA) has approved Tezspire®...

Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026

Amgen Inc. (NASDAQ: AMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an...

Company

Amgen Q4 Revenue Grows 9% to $9.9B on Strong Product Sales

Fineline Cube Feb 4, 2026

Amgen (NASDAQ: AMGN) reported fourth‑quarter 2025 revenue of USD 9.9 billion, up 9% year‑over‑year (YOY), bringing full‑year revenue...

Company Deals

Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift

Fineline Cube Feb 2, 2026

Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ: AMGN) for...

Company Deals

Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio

Fineline Cube Jan 8, 2026

Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held...

Company Drug

Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy

Fineline Cube Jan 4, 2026

Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making...

Company Drug

Amgen’s Uplizna Scores Third FDA Indication in Myasthenia Gravis

Fineline Cube Dec 15, 2025

Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients...

Company

Amgen Reports 12% YoY Sales Growth in Q3 2025, Raises Full‑Year Revenue Guidance

Fineline Cube Nov 7, 2025

US‑based biotech giant Amgen (NASDAQ: AMGN) posted its third‑quarter 2025 results, showing total sales of...

Company Deals

BeOne Secures $950 M Deal with Royalty Pharma for Tarlatamab Rights

Fineline Cube Aug 26, 2025

On August 26, 2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had...

Company

Amgen Reports 9% Revenue Growth in Q2 2025 Driven by Key Product Sales

Fineline Cube Aug 7, 2025

US-based biopharma Amgen Inc. (NASDAQ: AMGN) released its Q2 2025 financial results, showing a 9%...

Company Drug

Shanghai Henlius Biotech Earns GMP Certification for Prolia/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11

Fineline Cube Jul 3, 2025

China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice...

Company Drug

BeiGene and Amgen Report Positive Results for Tarlatamab in Chinese ES-SCLC Patients

Fineline Cube May 27, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology company proposing to rename...

Company Drug

Amgen’s Tepezza Approved in UK for Thyroid Eye Disease Treatment

Fineline Cube May 9, 2025

US biotech Amgen (NASDAQ: AMGN) announced that the UK’s Medicines and Healthcare products Regulatory Agency...

Amgen

Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Mabwell Bioscience Secures Second NMPA Approval for Denosu, China’s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma

BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer

Amgen’s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response

Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels

AstraZeneca’s Tezspire Gains Dual NMPA Approvals in China for Severe Asthma and Nasal Polyps Based on Pivotal Phase III Data

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Amgen Q4 Revenue Grows 9% to $9.9B on Strong Product Sales

Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift

Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio

Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy

Amgen’s Uplizna Scores Third FDA Indication in Myasthenia Gravis

Amgen Reports 12% YoY Sales Growth in Q3 2025, Raises Full‑Year Revenue Guidance

BeOne Secures $950 M Deal with Royalty Pharma for Tarlatamab Rights

Amgen Reports 9% Revenue Growth in Q2 2025 Driven by Key Product Sales

Shanghai Henlius Biotech Earns GMP Certification for Prolia/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11

BeiGene and Amgen Report Positive Results for Tarlatamab in Chinese ES-SCLC Patients

Amgen’s Tepezza Approved in UK for Thyroid Eye Disease Treatment

You Missed

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance